Clinical trials: Peritoneal Dialysis Patients
Peritoneal Dialysis, Chronic Kidney Disease
Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal Dialysis
The purpose of this study is to demonstrate that sevelamer hydrochloride is non-inferior to calcium acetate for the treatment of hyperphosphataemia in patients receiving peritoneal dialysis.
- Trial name
- NCT00196755
- Testing
- Sevelamer Hydrochloride (Renagel®), Calcium acetate (PhosLo® )
- Where
- 17 sites in Belgium, Denmark and 5 more
- Volunteers
- 138 people
- Sponsor
- Genzyme, a Sanofi Company
Hyperphosphatemia Patients on Peritoneal Dialysis
A Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal Dialysis
An open-label, single-arm clinical study of TS-172 in hyperphosphatemia patients on peritoneal dialysis
- Trial name
- NCT07548853
- Testing
- 'TS-172 20~60 mg/day
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
End Stage Renal Disease (ESRD), Diabetes
Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients
Primary Objective: To demonstrate that use of glucose sparing prescriptions, Dianeal, Extraneal, Nutrineal (D-E-N) versus Dianeal only, in diabetic (Type 1 and Type 2) Continuous Ambulatory Peritoneal Dialysis (CAPD) patients…
- Conditions
- End Stage Renal Disease (ESRD), Diabetes, CAPD
- Trial name
- EDEN (NCT01219959)
- Testing
- Dianeal, Dianeal, Extraneal, Nutrineal
- Where
- 16 sites in Colombia
- Volunteers
- 71 people
- Sponsor
- Vantive Health LLC
Anemia
A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.
This 2 arm study will compare the efficacy of monthly Mircera and epoetin alfa in peritoneal dialysis patients who self-inject at home or receive in-centre injections.
- Trial name
- NCT00442416
- Testing
- Epoetin alfa, methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 29 sites in United States
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche
Renal Insufficiency, Chronic
The Clinical Effects of Korean Adapted APD in Automated Peritoneal Dialysis Patients
The aim of this study is to assess the impact of "adapted" Automated Peritoneal Dialysis(APD) sequentially prescribed shorter and longer dwell exchanges with smaller and larger fill volumes in comparison with "conventional APD"…
- Trial name
- NCT01997385
- Testing
- KAPD-C, KAPD-A
- Where
- South Korea
- Volunteers
- 1,075 people
- Sponsor
- Fresenius Medical Care Korea
End-Stage Renal Disease
L-Carnitine as an Osmo-metabolic Agent for Peritoneal Dialysis
A major challenge of peritoneal dialysis (PD) therapy is the development of glucose-sparing strategies able to provide an efficacious ultrafiltration (UF) profile.
- Trial name
- NCT00851838
- Testing
- L-Carnitine
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- Iperboreal Pharma Srl
End Stage Renal Disease (ESRD)
Evaluate the Efficacy and Safety of Amino Acid (15) Peritoneal Dialysis Solution in Peritoneal Dialysis Patients with Malnutrition.
This is a multicenter, randomized, parallel controlled Phase IV clinical study to evaluate the safety and efficacy of amino acid (15) peritoneal dialysis solution in patients undergoing peritoneal dialysis with malnutrition in…
- Trial name
- NCT06597201
- Testing
- amino acid (15) peritoneal dialysis solution, glucose peritoneal dialysis solution
- Where
- 21 sites in China
- Volunteers
- 400 people
- Sponsor
- Chengdu Qingshan Likang Pharmaceutical Co., Ltd
Secondary Hyperparathyroidism
Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis
This study is designed to evaluate safety, pharmacokinetics and pharmacodynamics after single administration of KHK7580 for secondary hyperparathyroidism in patients receiving peritoneal dialysis.
- Trial name
- NCT02143271
- Testing
- KHK7580
- Where
- Japan
- Volunteers
- 13 people
- Sponsor
- Kyowa Kirin Co., Ltd.
End Stage Renal Disease (ESRD)
Bayston Multicenter Antimicrobial PD Catheter Safety Study
The study was designed to establish the safety of the Bayston Antimicrobial PD catheter that is impregnated with a "cocktail" of three well known anti-microbials
- Trial name
- Bayston (NCT02274896)
- Testing
- PD Catheter group
- Where
- 5 sites in Belgium, Netherlands and 1 more
- Sponsor
- Medical Components, Inc dba MedComp
End Stage Renal Disease, Peritoneal Dialysis-associated Peritonitis
A Prospective Clinical Study to Assess the Clinical Utility of Turbidity in Patients Using In-Home Peritoneal Dialysis
This study aims to determine if the CloudCath device can detect infections related to peritoneal dialysis (peritonitis) as fast or faster than the current standard methods used by patients and doctors to detect such infections.
- Conditions
- End Stage Renal Disease, Peritoneal Dialysis-associated Peritonitis, Peritonitis
- Trial name
- ACT (NCT05285436)
- Testing
- CloudCath System
- Where
- United States
- Volunteers
- 314 people
- Sponsor
- CloudCath
Iron Deficiency Anemia
2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.
This is a phase 3 clinical investigation. Patients who meet the eligibility criteria and provide signed informed consent will be randomized to receive one of two levels of Ferrlecit or oral iron in a 1:1:1 ratio.
- Trial name
- NCT00223977
- Testing
- Sodium Ferric Gluconate Complex, Oral Iron
- Where
- 43 sites in United States, Bulgaria and 6 more
- Volunteers
- 146 people
- Sponsor
- Watson Pharmaceuticals
End Stage Renal Disease
A Multiple-Dose Study of Oral Oseltamivir in Participants on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)
This study is designed to assess the pharmacokinetics (PK) and safety of oseltamivir and its metabolite oseltamivir carboxylate in participants undergoing routine HD and CAPD for end-stage renal disease (ESRD).
- Trial name
- NCT02617784
- Testing
- Oseltamivir
- Where
- New Zealand
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Anemia of End Stage Renal Disease
TARGTEPO Treatment for Anemia in PD US Trial
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment in Peritoneal Dialysis patients
- Trial name
- NCT02468414
- Testing
- MDGN201 TARGTEPO
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Heart Failure, Cardio-Renal Syndrome
A Clinical Study of the Safety and Efficacy of a Wearable Device (CLS UF) That Delivers Continuous Administration of Glucose to Recirculated Peritoneal Dialysis Fluid for the Purpose of Ultrafiltration in Patients With Congestive Heart Failure
A single-center, prospective, non-randomized, clinical and first-in-human study. Each patient will be studied during a single treatment session of ten hours.
- Trial name
- NCT02772146
- Testing
- CLS UF
- Where
- Germany
- Volunteers
- 2 people
- Sponsor
- Triomed AB
End-Stage Renal Disease
Study of Safety and Efficacy on New Peritoneal Dialysis Solutions
A major challenge of peritoneal dialysis (PD) therapy is the development of glucose-sparing strategies able to provide an efficacious ultrafiltration (UF) profile.
- Trial name
- NCT00858182
- Testing
- PD solution for nocturnal exchanges, PD solution for diurnal exchanges
- Sponsor
- Iperboreal Pharma Srl
Chronic Kidney Disease, End Stage Renal Disease
Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease
The purpose of this open-label extension study is to evaluate long-term efficacy and safety of roxadustat in maintaining hemoglobin (Hb) in participants with dialysis and non-dialysis chronic kidney disease (CKD) who have…
- Conditions
- Chronic Kidney Disease, End Stage Renal Disease, Anemia
- Trial name
- NCT01630889
- Testing
- Roxadustat
- Where
- 7 sites in United States, Puerto Rico
- Volunteers
- 15 people
- Sponsor
- Kyntra Bio
Peritoneal Dialysis, Hypertriglyceridemia
Effect of Extraneal (Icodextrin)on Triglyceride Levels in PD Patients
This is a Phase IV study evaluating triglyceride levels in peritoneal dialysis patients.
- Trial name
- NCT00397358
- Testing
- Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution
- Where
- 3 sites in United States
- Sponsor
- Vantive Health LLC
Secondary Hyperparathyroidism, End Stage Renal Disease
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis
This 6 month study will assess an investigational medication for patients on dialysis with secondary hyperparathyroidism. The study will look at the effects on parathyroid hormone, calcium and phosphorus levels.
- Trial name
- NCT00042653
- Testing
- AMG 073
- Volunteers
- 380 people
- Sponsor
- Amgen
Anemia
Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis
This is a open-label, prospective study comparing intravenous (IV) iron supplementation to standard care in anemic patents undergoing peritoneal dialysis.
- Trial name
- NCT00236938
- Testing
- Venofer and stable erythropoietin (EPO) regimen, stable erythropoietin (EPO) regimen
- Volunteers
- 121 people
- Sponsor
- American Regent, Inc.
End Stage Renal Disease, Continuous Ambulatory Peritoneal Dialysis
Open-label, Randomized Trial to Determine the Effect of Icodextrin Versus Dextrose (Dianeal 2.5%) in HOMA IR
Phase IV post-marketing study to evaluate the effect of Extraneal on the HOMA index in non-diabetic CAPD patients over the long-dwell exchange.
- Trial name
- ECOS (NCT01093547)
- Testing
- Blood samples, Measure of peritoneal ultrafiltrates
- Where
- Colombia
- Sponsor
- Vantive Health LLC